Atrial fibrillation
- 1 July 2001
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 3 (4) , 261-276
- https://doi.org/10.1007/s11936-001-0089-3
Abstract
The conversion of atrial fibrillation (AF) to normal sinus rhythm should be attempted in patients who present with this condition, as long as the cure is not worse than the disease itself. In young patients with normal hearts, AF has a small impact on morbidity and mortality. The primary indication for conversion in this population is often symptoms. In contrast, in patients with diseased hearts or who are older than 65 years, maintaining sinus rhythm may have a favorable impact on stroke risk, ventricular function, and symptoms. In the absence of normal sinus rhythm, these patients should receive anticoagulants. Rate control is the preferred first-line strategy for asymptomatic patients and patients presenting with a history of long-standing, persistent AF, making conversion and maintenance of sinus rhythm unlikely. Rate control may be used in patients who develop AF during an acute systemic illness, which will likely terminate with time or therapy. Conversion to sinus rhythm should be considered in patients with a first episode of AF, as unconverted AF tends to perpetuate itself. Conversion can be attempted if the duration of AF is less than 48 hours or if the patient has received anticoagulants when the duration is not known. Other indications for cardioversion are prolonged episodes in patients with otherwise infrequent episodes of paroxysmal AF, and in patients who refuse to take anticoagulants or in whom anticoagulation is contraindicated. After the patient is converted to sinus rhythm, the decision to initiate chronic drug therapy should be based on the presence of other cardiac and medical diseases that increase the risk of recurrence and serious symptoms in case of recurrence (such as hypertrophic cardiomyopathy or mitral stenosis). It is acceptable to manage patients with new-onset AF and normal cardiac function with cardioversion alone and not initiate chronic antiarrhythmic therapy afterwards. However, in patients with abnormal hearts (coronary artery disease, hypertensive or mitral valvular heart disease, and cardiomyopathy) AF is likely to recur, and such patients should be placed on antiarrhythmic medication.Keywords
This publication has 39 references indexed in Scilit:
- Cardiac arrhythmiasJournal of the American College of Cardiology, 2001
- Is Dual Site Better Than Single Site Atrial Pacing in the Prevention of Atrial Fibrillation?Pacing and Clinical Electrophysiology, 2000
- Inferior Vena Cava Loop of the Implantable Cardioverter Defibrillator Endocardial Lead: A Possible Solution to the Growth Problem in Pediatric ImplantationPacing and Clinical Electrophysiology, 2000
- Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-responseJournal of the American College of Cardiology, 2000
- Amiodarone to Prevent Recurrence of Atrial FibrillationNew England Journal of Medicine, 2000
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary VeinsNew England Journal of Medicine, 1998
- Preoperative Amiodarone as Prophylaxis against Atrial Fibrillation after Heart SurgeryNew England Journal of Medicine, 1997
- THE SURGICAL MANAGEMENT OF ATRIAL FIBRILLATIONAnnual Review of Medicine, 1997
- Long‐Term Follow‐Up of Patients Treated By Radiofrequency Ablation of the Atrioventricular JunctionPacing and Clinical Electrophysiology, 1995